NVAX is trading 5.7% up at $9.51, bouncing from recent softness. This comes as Novavax shareholders approved several key proposals at their annual meeting, the results of which were reported today, June 23, 2026.
- Shareholders elected three Class I directors to three-year terms and approved executive compensation on an advisory basis.
- Amendments to the company's 2015 Stock Incentive Plan and 2013 Employee Stock Purchase Plan were also approved.
- The stock is showing resilience following a period of volatility, with the news providing fresh company-specific context.